Valneva (VALN) Competitors

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Which has more risk and volatility, CPRX or VALN?

Catalyst Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.

Which has preferable earnings & valuation, CPRX or VALN?

Catalyst Pharmaceuticals has higher revenue and earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$491.73M	5.41	$71.41M	$1.31	17.04
Valneva	$158.54M	3.50	-$109.78M	-$0.13	-52.46

Do institutionals & insiders hold more shares of CPRX or VALN?

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media favor CPRX or VALN?

In the previous week, Catalyst Pharmaceuticals had 16 more articles in the media than Valneva. MarketBeat recorded 30 mentions for Catalyst Pharmaceuticals and 14 mentions for Valneva. Catalyst Pharmaceuticals' average media sentiment score of 0.81 beat Valneva's score of 0.56 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor CPRX or VALN?

Catalyst Pharmaceuticals received 468 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 75.11% of users gave Catalyst Pharmaceuticals an outperform vote while only 63.16% of users gave Valneva an outperform vote.

Company	Underperform	Outperform
Catalyst Pharmaceuticals	Outperform Votes 504 75.11%	Underperform Votes 167 24.89%
Valneva	Outperform Votes 36 63.16%	Underperform Votes 21 36.84%

Is CPRX or VALN more profitable?

Catalyst Pharmaceuticals has a net margin of 31.01% compared to Valneva's net margin of -4.35%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	31.01%	40.79%	34.87%
Valneva	-4.35%	-3.93%	-1.42%

Do analysts prefer CPRX or VALN?

Catalyst Pharmaceuticals currently has a consensus price target of $32.50, suggesting a potential upside of 45.61%. Valneva has a consensus price target of $17.00, suggesting a potential upside of 149.27%. Given Valneva's higher probable upside, analysts plainly believe Valneva is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Valneva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Catalyst Pharmaceuticals beats Valneva on 16 of the 19 factors compared between the two stocks.